## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invitation</td>
<td>2</td>
</tr>
<tr>
<td>Committees</td>
<td>4</td>
</tr>
<tr>
<td>Awards</td>
<td>6</td>
</tr>
<tr>
<td>Executive Boards</td>
<td>7</td>
</tr>
<tr>
<td>IFCC Travel Scholarship</td>
<td>8</td>
</tr>
<tr>
<td>Sunday October 22</td>
<td>10</td>
</tr>
<tr>
<td>Monday October 23</td>
<td>12</td>
</tr>
<tr>
<td>Tuesday October 24</td>
<td>17</td>
</tr>
<tr>
<td>Wednesday October 25</td>
<td>22</td>
</tr>
<tr>
<td>Closed Meetings</td>
<td>27</td>
</tr>
<tr>
<td>Exhibition and Sponsors</td>
<td>28</td>
</tr>
<tr>
<td>Exhibition Area Map</td>
<td>47</td>
</tr>
<tr>
<td>Satellite Meetings</td>
<td>48</td>
</tr>
<tr>
<td>General Information</td>
<td>49</td>
</tr>
<tr>
<td>Congress Venue</td>
<td>54</td>
</tr>
<tr>
<td>Durban International Convention Centre Map</td>
<td>55</td>
</tr>
<tr>
<td>Sponsors</td>
<td>56</td>
</tr>
</tbody>
</table>
Multi-omics, laboratory medicine & personalized medicine

On behalf of the Congress Organising Committee and the South African Association for Clinical Biochemistry (SAACB), it gives me great pleasure to invite colleagues to the Congress of Clinical Chemistry and Laboratory Medicine (WorldLab). This meeting is also being organized in co-operation with the African Federation of Clinical Chemistry (AFCC). It is the first time that such a meeting is being held in Africa and reflects the growing importance of this continent.

WorldLab 2017 promises to be one of the best with a unique blend of innovative science, evidence based laboratory medicine and an emphasis on personalized medicine. This reflects the changing directions of science and medicine with greater attention being paid to prevention and risk stratification. Because of the expanding role of laboratory medicine, we plan to combine this meeting with other clinical specialities which will underscore the overarching influence of laboratory medicine in health care.

The scientific and social programmes will provide opportunities to forge new collaborations and to connect with leaders of the diagnostic industry at the IVD product show linked to the three-day conference/workshop program. We are confident that this meeting will attract delegates from all the member IFCC societies and that each regional federation will play an important role in making this meeting one of the best in recent times.

Africa is traditionally associated with its magnificent wildlife and unique cultural diversity. South Africa provides an opportunity to discover both of them. Durban, a melting pot for African and Indian cultures, is a coastal city with a tropical climate and pristine beaches and surfing. Namibia, Zambia, Zimbabwe, Mozambique and Botswana are close by and can easily be assessed by air via Johannesburg. Durban is the site for various clinical trials and some of the major breakthroughs in the management of patients with HIV have been made here.

The kingdom of KwaZulu- Natal, South Africa beckons and extends a warm welcome to all of you. It’s a unique cultural destination littered with historical sites of past battles fought between the Zulus and the British forces. Hiking in the majestic Drakensburg Mountains, barely an hour away, is an activity not to be missed. The famous Table Mountain in Cape Town and the world renowned Kruger National Park are easily accessible.

The Organizing Committee of WorldLab, the South African Association for Clinical Biochemistry and African Federation of Clinical Chemistry look forward to welcoming you to Durban in the Royal Kingdom of KwaZulu-Natal, South Africa in 2017.

Professor Rajiv Erasmus,
Congress President and Chairman of the Organizing Committee, WorldLab 2017, Durban

Professor Tahir S. Pillay,
Congress President and Chairman of the Scientific Programme Committee, WorldLab 2017, Durban
President, South African Association for Clinical Biochemistry and Laboratory Medicine
Dear Friends and Colleagues,

It is my great pleasure to announce that the 23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab 2017) in conjunction with the 57th Meeting of the South African Association for Clinical Biochemistry and Laboratory Medicine and the 5th Congress of the African Federation of Clinical Chemistry, will be held in Durban, South Africa, October 22nd – October 25th, 2019 and to invite you to take part to this very newsworthy scientific event.

Whether you work in a hospital, a university, in private practice or in the diagnostics industry IFCC WorldLab 2017 in Durban will be the place to come. The chance to combine leading world experts with the unique treasures of Durban represents a valuable opportunity to allow people coming from all over the world to gather and exchange ideas. This will be a special conference held in the modern Durban International Convention Center, an ideal location to participate to a very advanced scientific presentations combined with the largest exhibition of in vitro diagnostic products..

IFCC WorldLab 2017 will cover all the scientific and technological aspects of Laboratory Medicine. We are expecting participants from all over the world and a great contribution from exhibitors. A well balanced program of oral and poster presentations, and dedicated workshops, will guarantee an efficient exchange of ideas and allow productive discussions.

I am certain that the scientific program is of high quality and interest containing innovative ideas and of direct relevance to modern laboratory medicine. The accompanying industrial exhibition will provide information and advice on the most up to date equipment, diagnostics, informatics and professional practice.

These are exciting times in the world of laboratory medicine. Therefore, laboratory medicine specialists and the diagnostic industry have a responsibility to work together to convert data into knowledge which can be used to add value to patients health.

I look forward to welcoming you in Durban

Yours sincerely,

Prof. Maurizio Ferrari
IFCC President
COMMITTEES

CONGRESS ORGANISING COMMITTEE

R.T. Erasmus
Congress President, Congress Organising Committee Chair

T.S. Pillay
Congress President, Scientific Programme Committee Chair

N. Crowther
Abstracts

V. Steenkamp
Social Programme

A. Zemlin
Finance

R.T. Erasmus
IFCC C-CC Liaison

A.B. Okesina
AFCC Liaison

INTERNATIONAL SCIENTIFIC COMMITTEE

T.S. Pillay (South Africa),
K. Adeli (Canada)
J. Delanghe (Belgium)
R.T. Erasmus (South Africa)
T. Matsha (South Africa)
S. Sandberg (Norway)
M. Turzyniecka (South Africa)
A. Zemin (South Africa)
D.B. Sacks (USA)
I. Young (United Kingdom)
P. Gillery (France)
A.B. Okesina (Nigeria)
M. M. Blanes Gonzales (Paraguay)
N. Crowther (South Africa)
COMMITTEES

INTERNATIONAL SCIENTIFIC ADVISORY BOARD

R.T. Erasmus
Congress President, Congress Organising Committee Chair

T.S. Pillay
Congress President, Scientific Programme Committee Chair

S. Belazzouq (Algeria)
H. Morris (Australia)
A. Griesmacher (Austria)
J.P. Chapelle (Belgium)
A.J. Grosz (Bolivia)
R. Jadric (Bosnia Herzegovina)
K. Tzatchev (Bulgaria)
E. Aranda (Chile)
D. Pašalić (Croatia)
E.A. Marcel (Cuba)
T. Zima (Czech Republic)
M.M. Saldarreaga Zambrano (Ecuador)
M. Shaarawy (Egypt)
A. Tamm (Estonia)
G. Abebe (Ethiopia)
R.J. Ignacio (Philippines)
P. Laitinen (Finland)
P. Gillery (France)
A.L. Maselli (Guatemala)
A. Miseta (Hungary)
I. Olafsson (Iceland)
M.V.R. Reddy (India)
J. Kumalawati (Indonesia)
P. Pasalar (Iran)
A. Mosca (Italy)
J. Song (Korea)
D. Ozolins (Latvia)
C. Haddad (Lebanon)
D. Vitkus (Lithuania)
J.F. Munoz-Valle (Mexico)
N. Gligorovic Barhanovic (Montenegro)
L. Chabraoui (Morocco)
B. Kumar Yadav (Nepal)
E.O. Agbedana (Nigeria)
J. Petter Berg (Norway)
J. Ortellado De Canese (Paraguay)
G. Sypniewska (Poland)
J.T. Guimarães (Portugal)
L. Khorovskaya (Russia)
N. Majkić-Singh (Serbia)
B. Mozina (Slovenia)
P. Bjellerup (Sweden)
A. Al-Khatib (Syrian Arab Republic)
J.W. Janssen (The Netherlands)
D. Yucel (Turkey)
Q.F.B.C.E. Lopez (Uruguay)
R. Christenson (USA)
P. Thien Ngoc (Vietnam)
H. T. Marima-Matarira (Zimbabwe)
AWARDS

IFCC DISTINGUISHED AWARDS 2017

The IFCC is pleased to announce the names of the winners of the eight 2017 IFCC Distinguished Awards. The IFCC Distinguished Awards are bestowed to laboratory medicine professionals to recognize their outstanding achievements, publicize their exceptional research and contributions to medicine and healthcare, and encourage the overall advancement of clinical chemistry and laboratory medicine.

Professor Yuk-Ming Dennis LO (HK)
IFCC Distinguished Clinical Chemist Award

Doctor Jocelyn M. B. HICKS (US)
IFCC Henry Wishinsky Award for Distinguished International Services

Professor Nader RIFAI (US)
IFCC Award for Distinguished Contributions in Education

Associate Professor Susan BRANFORD (AU)
IFCC Award for Distinguished Contributions in Molecular Diagnostics

Doctor Eleftherios DIAMANDIS (CA)
IFCC Distinguished Award for Laboratory Medicine and Patient Care

Professor. Mathias M. MÜLLER (AT)
IFCC-Robert Schaffer Award for Outstanding Achievements in the Development of Standards for Use in Laboratory Medicine

Doctor Jack H. LADENSON (US)
IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics

Doctor Rojeet SHRESTHA (NP)
IFCC Young Investigator Award
EXECUTIVE BOARDS

IFCC -International Federation of Clinical Chemistry and Laboratory Medicine

Prof. Maurizio Ferrari  
President

Prof. Howard Morris  
President-elect (2017)

Dr Graham Beastall  
Past President (2015-2016)

Prof. Sergio Bernardini  
Secretary

Prof. Tomris Ozben  
Treasurer

Dr Rolf Hinzmann  
Corporate Rep.

Dr Rosa Sierra-Amor  
Member

Prof. Vanessa Steenkamp  
Member

African Federation of Clinical Chemistry

Prof. Adekunle B. Okesina  
President

Prof. Rajiv T. Erasmus  
President-elect

Prof. Vanessa Steenkamp  
Past President

Prof. Hilde T. Marima-Matarira  
Secretary

Prof. Angela Amayo  
Treasurer

Dr Mabel Charles - Davies  
Member-at-large

Mr. Gizachew Akalu  
Member-at-large

South African Association of Clinical Biochemistry and Laboratory Medicine

Prof. Tahir S. Pillay  
President

Prof. Rajiv T. Erasmus  
Past President

Dr Magdalena Turzyniecka  
Secretary

Prof. George van der Watt  
Scientific Officer

Prof. Nigel Crowther  
Member

Dr Fierdoz Omar  
Treasurer
IFCC TRAVEL SCHOLARSHIP

ABDULLAH I Naima Shukri - KENYA
ABIMBOLA OnaoluwA Anna - NIGERIA
ADHAM Latifah Anandari - INDONESIA
AJAYI Ebenezer Idowu Olatunbosun - NIGERIA
AJAYI Oluophe Oluwemi - NIGERIA
AKINMOLA Oluhayode Oluwumi - NIGERIA
ALABA Habtamu Asrat - ETHIOPIA
ALAJE Abiodun Kofoworola - NIGERIA
ANJORIN Funmilola Favour - NIGERIA
ARICHA Stephen Akuma - KENYA
ASFAW Ephrem Tsegay - ETHIOPIA
ASOROSE Solomon Abiola - NIGERIA
AYOADE Olufisayo Gabriel - NIGERIA
AZEEZ Ademola Akinkunmi Daniel - NIGERIA
BHATT Rajendra Dev - NEPAL
CHANDRASEKARAN Shumugpriya - INDIA
CHIBUYE Sylvia - ZAMBIA
CHILUNDU Ireen - ZAMBIA
CHIVETO-AACB Dexter Tadiwanashe - ZIMBABWE
CHUKWUKELU Ekene Emmanueluka - NIGERIA
COLE Justine - SOUTH AFRICA
DADA - Adeyemi Oluwasen - NIGERIA
DATTA Sudip Kumar - INDIA
DAVIDS Nawaal - SOUTH AFRICA
DAVIDS Saarah Fatoma Gadija - SOUTH AFRICA
DLAMINI Immaculate Siphelele - SOUTH AFRICA
EL MAATAOUI Aissam - MOROCCO
EWORO Ekong Raymond - NIGERIA
FELEKE SiFegebril Teshome - ETHIOPIA
FUMA Siphokazi Precious - SOUTH AFRICA
GOMA Chinda Eveline - ZAMBIA
GOUNDEN Verena - SOUTH AFRICA
ISLAM Mohammed Ataul - SOUTH AFRICA
JALAVU Thumeka Portia - SOUTH AFRICA
JOHN Mary Ndinda - KENYA
JOY Ashish K - INDIA
KHAMBULE Lungile - SOUTH AFRICA
KIPANDULA Wakisa Lenard - MALAWI
LAWAL Akeem Oyeyemi - NIGERIA
LEE-E'SILVA Derryn Audrey - SOUTH AFRICA
LUKDEN Stephen Mawun - NIGERIA
MABAYA Lucy Chekenya - ZIMBABWE
MAJID Hafsa - PAKISTAN
MALAMBA-AACB Chikondi Agness - MALAWI
MAMPUNYE Lwando - SOUTH AFRICA
MBU Desiree Lem - SOUTH AFRICA
MHANDIRE - AACB Kudakwashe - ZIMBABWE
MOREMI Kelebogile Elizabeth - SOUTH AFRICA
MOSLAH Bilel - TUNISIA
MOTSHWARI Dipuo Dephney - SOUTH AFRICA
MUDHLULI Taona Emmah - ZIMBABWE
MUKWAKWAMI Memory Mazhindu - ZIMBABWE
MUTEMBEDZA Shamiso - ZIMBABWE
NAGEL Susanna Lizette - SOUTH AFRICA
NAJJAR Dana Osama - PALESTINE
NDLOVU Mbali Thembekile - SOUTH AFRICA
NEUPANE Sunita - NEPAL
NGXAMNGXA Unathi - SOUTH AFRICA
NTULI Philisiwe - SOUTH AFRICA
NYANGENA Simon Onsongo - KENYA
OBIANYIDO Ozioma Ebe - NIGERIA
OBILO Rugesi - NIGERIA
OBISANJU OmoBolanle Biliqees - NIGERIA
ODO Alfred Ibu - NIGERIA
OGUNLEYE Adeyemi - NIGERIA
OJELABI Ifeoluwa Hephziba - NIGERIA
OKOLI Stephen Uchechukwu - NIGERIA
OKUNDELA Abisola Oyedele - SOUTH AFRICA
OLADELE Funmilola Comfort - NIGERIA
OLAIWA Serah Mayowa - NIGERIA
OLAWALE Olatunbosun Oladipupo - NIGERIA
ONYENEKU Chinele Pamela - NIGERIA
PEMA - AACB Aarti Kanthi - SOUTH AFRICA
RALEFATANE Maile George - SOUTH AFRICA
RAMPUL Ashlin - SOUTH AFRICA
RUSH Jodi Alan - SOUTH AFRICA
SAHLE Selam Niguse - ETHIOPIA
SELOWO Temitope Toluse - NIGERIA
SHERAZI Noreen Abbas - PAKISTAN
TEREFE Alemayehu Reta - ETHIOPIA
TESSEMA Belay - ETHIOPIA
TORROREY Rispah Sawe - SOUTH AFRICA
UGWU Prince Ifeji - NIGERIA
VAN DER MERWE Nicole - SOUTH AFRICA
WARASALLY Zain - SOUTH AFRICA
WEALE Cecil Jack - SOUTH AFRICA
WUBETU Gizachew Yismaw - ETHIOPIA
ZABLON Jeremiah Omari - KENYA
IFCC ROCHE TRAVEL SCHOLARSHIP

ABULSOUD Ahmed Ibrahim - EGYPT
BANERJEE Parama - INDIA
CHAABOUNI Yassine - TUNISIA
CHAWE Adon - ZAMBIA
GAUTAM Narayan - NEPAL
MAKURA Alfred - ZIMBABWE
OGUNDAJO Akimwumi Tosin - NIGERIA
OMUSE Geoffrey Amuka - KENYA
WAKA Feyssa Challa - ETHIOPIA
YADAV Binod Kumad - NEPAL
ZAMORA MARROQUIN Elena Maria - GUATEMALA

IFCC JOCELYN HICKS TRAVEL SCHOLARSHIPS

DAKA Victor - ZAMBIA
MITRA Prasenjit - INDIA
MULWA Evelyn - KENYA
NGUYEN Ngoc Lan Thi Ngoc - VIETNAM
Sunday October 22

17.30-18.45 OPENING CEREMONY

Welcome IFCC President, Welcome Congress President, Welcome SAACB President

AWARDS PRESENTATION

M. Ferrari (Italy)

Professor Yuk-Ming Dennis LO (HK)
IFCC Distinguished Clinical Chemist Award

Doctor Jocelyn M. B. HICKS (US)
IFCC Henry Wishinsky Award for Distinguished International Services

Professor Nader RIFAI (US)
IFCC Award for Distinguished Contributions in Education

Associate Professor Susan BRANFORD (AU)
IFCC Award for Distinguished Contributions in Molecular Diagnostics

Doctor Eleftherios DIAMANDIS (CA)
IFCC Distinguished Award for Laboratory Medicine and Patient Care

Professor. Mathias M. MÜLLER (AT)
IFCC-Robert Schaffer Award for Outstanding Achievements in the Development of Standards for Use in Laboratory Medicine

Doctor Jack H. LADENSON (US)
IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics

Doctor Rojeet SHRESTHA (NP)
IFCC Young Investigator Award

OPENING LECTURE

Salim S. Abdool Karim (South Africa)

18.45-21.00 WELCOME GET TOGETHER
HIV in women in Africa: new evidence from phylogenetic, genomic and protein research

Chair: Tahir S. Pillay

Salim S. Abdool Karim (South Africa)

Salim S. Abdool Karim, MBChB, PhD, DSc (honoris causa) is a clinical infectious diseases epidemiologist widely recognised for his ground-breaking scientific contributions in HIV prevention and treatment. He is Director of CAPRISA - Centre for the AIDS Programme of Research in South Africa; Pro Vice-Chancellor (Research), University of KwaZulu-Natal; CAPRISA Professor of Global Health at Columbia University, Adjunct Professor of Medicine, Cornell University and Associate Member of The Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University. His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents which have been used in several HIV vaccine candidates and his clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients.

He chairs the UNAIDS Scientific Expert Panel and is a member of both the WHO HIV-TB Task Force and the WHO Expert Panel on STIs and HIV. He is an elected Fellow of the World Academy of Sciences, African Academy of Sciences, Academy of Science in South Africa, Royal Society of South Africa and American Academy of Microbiology. He is a Foreign Associate Member of the US National Academy of Medicine. He serves on the Boards of Lancet-Global Health, Lancet-HIV and the New England Journal of Medicine.
09.00-11.00  SYMPOSIUM 1 (Conference 1)

**Laboratory Reference Intervals: Global Initiatives and Harmonization Challenges**
*Chair: K. Adeli (Canada)*

- Global Initiatives on Reference Intervals and IFCC C-RIDL Recommendations
  *K. Ichihara (Japan)*

- Closing the Gaps in Pediatric Reference Intervals: the CALIPER and CHMS initiatives
  *K. Adeli (Canada)*

- Harmonisation of Laboratory Reference Intervals: the Australian Experience
  *J. Tate (Australia) (TBC)*

09.00-11.00  SYMPOSIUM 2 (Conference 2)

**Applying Big Data in the Improvement of Laboratory Practice**
*Chair: Y.V. Zhang (USA)*

- Applying big data in the selection of optimal test platform
  *Y. V. Zhang (USA)*

- Translation from big data to clinically useful tests
  *Z. Zhao (USA)*

- Applying big data of patient test results in the detection of lab errors and monitoring quality control
  *M. Jin (USA)*

09.00-11.00  SYMPOSIUM 3 (Conference 3)

**Affordable diagnostics for Africa**
*Chair: J. Delanghe (Belgium)*

- A turbidimetric method for assaying serum C-reactive protein based on phosphocholine interaction
  *P.L. Tugirimana (Rwanda)*

- Keratin glycation: an alternative for diabetes testing
  *A. S. Kishabongo (D.R. of Congo)*

- Affordable microalbumin testing
  *J. Delanghe (Belgium)*

- Implementation of point-of-care diagnostics for infectious diseases in resource-limited settings
  *A. Shapiro (USA)*

09.00-11.00  IFFC S1: IFCC SD (Conference 4)

**Recent Advances in Standardisation**
*Chair: G. Miller (USA)*

- Commutability issues in standardization of laboratory measurement procedures
  *G. Miller (USA)*

- Standardization of Pregnancy-Associated Plasma Protein A
  *S. Wittfooth (Finland)*

- Standardization of urine albumin assays
  *L. Bachmann (USA)*

- Standardization of CSF proteins
  *K. Blennow (Sweden)*

11.00-11.45  BREAK
**Monday October 23**

**11.45-12.30  PLENARY 1 (Conference 1)**

**Liquid biopsy:** circulating plasma free DNA (cfDNA) as a novel prognostic and diagnostic marker in disease states  
*Chair: T. Ozben (Turkey)*

- *R. Thakker (United Kingdom)*

Rajesh Thakker is the May Professor of Medicine at the University of Oxford, and a Fellow of Somerville and Harris Manchester Colleges, Oxford. His main research interests include the molecular basis of disorders of calcium homeostasis and he has authored over 350 publications, which have included peer-reviewed papers in the New England Journal of Medicine, Nature, Nature Genetics, Journal of Clinical Investigation and Lancet Journals. He is a Consultant Endocrinologist who provides expertise in the fields of neuroendocrine tumours (NETs), and disorders of calcium and phosphate metabolism. He was previously Professor of Medicine at The Royal Postgraduate Medical School, The Hammersmith Hospital, London, until 1999, when he took up his present position in Oxford. He has served on the MRC Physiological Medicine and Infections Board (2000-2005), the Council for the Society for Endocrinology (2003-2006), and as Chairman of the National Institute of Health Research (NIHR) / MRC Efficacy and Mechanisms Evaluations (EME) Board (2008-2016). He has been the recipient of many prizes which include: Young Investigator Award from the American Society for Bone and Mineral Research (ASBMR), USA (1988); the Raymond-Horton Smith Prize (Cambridge University, UK) (1994); the Society for Endocrinology (UK) medal (1995); the European Journal of Endocrinology Prize (EFES) (1998); WPJ Jackson Memorial Lecture, Society for Endocrinology, Metabolism, and Diabetes in South Africa (SEMSDA) (1998); the Graham Bull Prize from the Royal College of Physicians (UK) (1999); Bernard Pimstone Memorial Lecture, SEMSDA (2003); the Parathyroid Medal from the Fondazione Raffaella Becagli (FIRMO) (2012); the Jack W. Coburn Endowed Lectureship from the American Society of Nephrology (2012); the Louis V Avioli Founder’s Award from the ASBMR (USA) (2009); the International Research Prize from the Austrian Society for Bone and Mineral Research (2015); and the Dale Medal from the Society for Endocrinology (UK) (2015). Professor Thakker was elected to the Fellowship of the Royal Society (FRS) in 2014.

**10.00-17.00  EXHIBITION OPEN AREA**

**12.30-14.00  POSTER SESSION**

**12.30-14.00  LUNCH SYMPOSIUM 1 (Conference 1)**

**Liquid biopsy:** circulating plasma free DNA (cfDNA) as a novel prognostic and diagnostic marker in disease states  
*Chair: T. Ozben (Turkey)*

- Plasma fetal DNA for prenatal screening  
  *U. Gormus (Turkey)*

- Liquid biopsy in tumours diagnostics; focus on prostate tumour  
  *A. Tomasi (Italy)*

- Liquid biopsy: Circulating free tumour DNA (ctDNA) and Circulating Tumour Cells (CTC) as novel biomarkers  
  *T. Ozben (Turkey)*

**12.30-14.00  LUNCH SYMPOSIUM 2 (Conference 2)**

**Frontiers in Endocrinology**  
*Chair: S.J. Soldin (USA)*

- Role of mass spectrometry in improving diagnosis and treatment of thyroid and adrenal diseases  
  *S.J. Soldin (USA)*

- Diurnal variation of steroid hormones and their reference intervals using mass spectrometric analysis  
  *T. Parikh (USA)*

- Methods and interferences in the analysis of haemoglobin A1c. Is there an ideal method?  
  *D.B. Sacks (USA)*
### 12.30-14.00 LUNCH SYMPOSIUM 3 (Conference 3)

**AFCC Symposium-Infections and Diabetes**  
*Chair: H. Matarira (South Africa)*

- E. Sobingwi (TBA)
- *Role of Iron in the development of diabetes*  
  A. B. Okesina
- *HIV and Diabetes*  
  N. Levitt
- H. Matarira (TBA)

### 12.30-14.00 LUNCH SYMPOSIUM 4 (Conference 4)

**Biomarkers in urological cancer**  
*Chair: T. Zima (Czech Republic)*

- Receptor for advanced glycation end products in kidney cancer  
  T. Zima/ M. Kalousová (Czech Republic)
- Epigenetic nucleosomics biomarkers for detection and management of urological cancer  
  S. Holdenrieder (Germany)

### 14.00-16.00 IFFC S1: IFCC EMD (Conference 1)

**Evidence-Based Laboratory Medicine (EBLM); a global perspective**  
*Chair: A. Zemlin (South Africa)*

- What is EBLM and why do we need it?  
  C.M. Florkowski (New Zealand)
- Why do Guidelines vary so much? And how do we recognise a good one?  
  J. Wils (France)
- Perceived competencies and need of training regarding the practice of Evidence Based Medicine among medical laboratory professionals  
  K. Rodriguez-Capote (Canada)
- Getting the EBLM message out to the world- new resources  
  H. Fares-Taie (Argentina)

### 14.00-15.00 Educational Workshop 1 (Conference 2)

**Infectious disease management through innovative blood cell analysis: Rapid diagnosis of the origin of fever and anaemia in developing countries for improved outcomes.**  
*Chair: Professor Theresa Coetzer*  
*Scientific Coordinator: Petra Biggins*

- Welcome and Introduction  
  Prof Theresa Coetzer
- Haematology analysers in Infectious Diseases  
  Prof Andre van der Ven
- Novel flow cytometric approach to automated malaria diagnostics - performance evaluation of Sysmex XN-30 analyser  
  Dr Ivashen Pillay

- Q&A session  
  Prof Theresa Coetzer
Risk Management and its utility in the clinical laboratory
Chairs: T.S. Pillay (South Africa), P.K. Suraj (India)

Preventing and minimizing laboratory errors and nonconformances; continual improvement, corrective and preventive actions
E. Frank (India), T.S. Pillay (South Africa)

Risk management and its utility in the clinical laboratory
S. Turner (New Zealand)

Waspalm/IFCC joint symposium
Genomic analysis in personalized diagnostics
Chairs: R. Verna (Italy), M. Ferrari (Italy)

The ethics of genetics ownership of genetic information
I. Loftus (South Africa)

Circulating cell-free DNA in cancer and transplantation
M. Oellerich (Germany)

The clinical value of laboratory
R. Verna (Italy)

Pre-Analytical quality work in Medical Labs
Chair: M. Nybo (Denmark)

A structured walkthrough of the different phases of a quality assessed blood sampling process
E. R. B. Petersen (Denmark)

Preanalytical quality assessment in Medical Labs
M. Nybo (Denmark)

Test management – are we there yet?
R. McGrail (Denmark)

Improving Healthcare Outcomes In The Emergency Setting
Chair: Prof. Maurizio Ferrari

cTroponins: similar but not quite the same
Dr Stefano Favero

Procalcitonin for management of the septic patient
Dr Nicky Oosthuizen

Laboratory investigations in the diagnosis and management of parathyroid disorders
S. Vasikaran (Australia)

Endocrine cases and data interpretation
L. Lai (Malaysia)

Vitamin D to Prevent Osteoporosis: Critical Levels and Mechanisms of Action
H. Morris (Australia)
### Workshop 5 (Conference 3)

**Role of biomarkers in precision medicine**  
*Chairs: R.H.N. van Schaik (Netherlands), R. de Jonge (Netherlands)*

- Clinical implementation of pharmacogenetics: do you already have your DNA passport?  
  *R.H.N. van Schaik (Netherlands)*

- Cell-free DNA as a new biomarker for monitoring lung cancer  
  *D. van den Broek (Netherlands)*

- Predicting MTX nonresponders in adult and juvenile arthritis  
  *M. Bulatović Ćalasan (Netherlands), R. de Jonge (Netherlands)*

### Workshop 6 (Conference 4)

**Biomarkers in clinical chemistry - omics galaxies**  
*Chair: L. Kluijtmans (Netherlands)*

- The diagnostic value of untargeted metabolomics in the era of whole exome  
  *J. Jans (Netherlands)*

- Untargeted crossomics in a diagnostic setting  
  *L. Kluijtmans (Netherlands)*

- Clinical Glycomics: a nurture level on top of genes and proteins  
  *M. van Scherpenzeel (Netherlands)*
Scientific Programme
Tuesday October 24

09.00-11.00 SYMPOSIUM 6 (Conference 1)

COLABIOCLI: Dengue, Chikungunya and Zika: Impact and intervention in Latin-American countries
Chair: M. M. Blanes González (Paraguay)

Chikungunya, Dengue and Zika, a challenge for the Cuban professionals and population
E. M. Abraham (Cuba)

Lessons from the epidemics of Dengue, Chikungunya and Zika in Dominican Republic
R. Skewes-Ramm (Dominican Republic)

Paraguayan experience-Chikungunya: assessment and impact in Public Health in Paraguay. Correlation with values reported in Latin American region
M.M. Blanes González (Paraguay)

09.00-11.00 SYMPOSIUM 7 (Conference 2)

Clinical Laboratory Practice for Bone Turnover Markers
Chair: H. Morris (Australia)

Bone turnover markers in diagnosis and monitoring of metabolic bone disease; choosing the best marker for that patient, decision limits and treatment targets
S. Vasikaran (Australia)

Bone Markers for Metastatic Bone Disease and Cancer Therapy Related Bone Disease
Q.H. Meng (USA)

Bone Turnover Marker measurement; physiological principles and analytical issues; providing the optimum analytical service
H. Morris (Australia)

09.00-11.00 SYMPOSIUM 8 (Conference 3)

Advances in TB diagnostics
Chair: I. Verma (India)

TB diagnosis: essentials the clinician needs from the laboratory now and in the future?
K. Dheda (South Africa)

Regulatory T cell & Programmed Death Receptor-1 in human Tuberculosis: Implications in diagnosis, immunotherapy and vaccination
D.K. Mitra (India)

HIV-TB synergism in co-infection: challenges in diagnosis & disease management
S. Arora (India)

In vivo expressed mycobacterial genes/proteins as diagnostic biomarkers for tuberculosis
I. Verma (India)

9.00-11.00 IFCC S3: IFCC EMD (Conference 4)

IFCC EMD: Implementing Cancer Genomics in Low Resource Settings
Chair: L.J. Kricka (USA)

Genomic medicine: learning how to walk before we run
M. Ferrari (Italy)

Pharmacogenetic applications in oncology
R.H.N. van Schaik (Netherlands)

Advanced laboratory techniques for low resource settings
B. J., USA

11.00-11.45
The Nanobody revolution in laboratory diagnostics

Chair: S. Muyldermans (Belgium)

Serge Muyldermans is Professor, Department of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium. His main interest is in developing biochemical tools to investigate the molecular structure and function of chromatin (nucleosomes).

As such, cloning genes, screening genomic and cDNA libraries, site-directed mutagenesis, and producing recombinant proteins were part of the repertoire. Following the serendipitous discovery of natural occurrence of functional heavy chain only antibodies in camelids he developed a streamlined method to identify rapidly the antigen-specific, single-domain antibody fragments derived from the unique Heavy chain antibodies of camelids.

Because these antibodies lack light chains, the antigen-binding domain must comprise only the single variable domain of the immunoglobulin heavy chain. Thus, they developed the technology to immunize a dromedary, llama, or alpaca; to clone the genes for the single variable domain (now known as Nanobody); and to select the antigen-binding domains by phage display.

Furthermore, they have explored possible applications for these nanobodies where their small size and biochemical properties are beneficial. The discovery of camel Heavy-chain antibodies and the applications of their unique single variable antigen-binding domain (now referred to as Nanobodies) led to the publication of over 150 articles in peer reviewed international journals, many of which appeared in top journals. In January 2002, he was co-founder of ‘Ablynx’, a spin-off company that generates Nanobodies for therapeutic purposes. Ablynx is currently employs about 300 people and has several Nanobodies in clinical trials.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30-14.00</td>
<td>LUNCH SYMPOSIUM 7 (Conference 3)</td>
<td>Practical aspects of taking laboratory to next step</td>
<td>A. Gupta (India)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measurement of uncertainty- Its practical application in a laboratory setup of a large tertiary care hospital</td>
<td>A. Gupta (India)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moving ahead with six sigma</td>
<td>S. Sharma (India)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>How to achieve comparable thyroid function test across laboratories</td>
<td>B. Das (India)</td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>LUNCH SYMPOSIUM 8 (Conference 4)</td>
<td>Development of a clinical case bank for promoting the practice of Eblm</td>
<td>K. Ichihara (Japan), R.T. Erasmus (South Africa)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The protocol for building clinical case bank for laboratory diagnosis by international collaborations</td>
<td>K. Ichihara (Japan)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Utility of the clinical case bank for improved clinical diagnosis and management of hematological malignancies</td>
<td>M.A. Sumon (Bangladesh)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Utility of the clinical case bank for improved clinical diagnosis and management of collagen diseases</td>
<td>M. Esser (South Africa)</td>
</tr>
<tr>
<td>14.00-16.00</td>
<td>IFCC S4: IFCC CPD (Conference 1)</td>
<td>Value of Laboratory medicine in healthcare delivery and clinical outcomes</td>
<td>K. Adeli (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anatomy of a value proposition for laboratory medicine</td>
<td>H. Morris (Australia)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Critical review of the evidence supporting the value of lab medicine in clinical care</td>
<td>K. Adeli (Canada)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Demonstrating the value of laboratory tests: a clinical and economic perspective</td>
<td>W. van der Helm (Switzerland)</td>
</tr>
<tr>
<td>14.00-16.00</td>
<td>SYMPOSIUM 9 (Conference 3)</td>
<td>Advanced glycation products (AGEs) in diabetes mellitus and chronic diseases</td>
<td>P. Gillery (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-translational modification derived products (PTMDPs) and AGEs : bioactive components involved in human pathophysiology</td>
<td>P. Gillery (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AGEs as biomarkers in diabetes and chronic diseases</td>
<td>R. Erasmus (South Africa)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-Invasive Glycation Testing</td>
<td>J. Delanghe (Belgium)</td>
</tr>
<tr>
<td>14.00-16.00</td>
<td>IFCC S5: IFCC EB (Conference 4)</td>
<td>Facing the future of Alzheimer's disease: the value of the medical laboratory</td>
<td>S. Bernardini (Italy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measurement and clinical utility of CSF proteins</td>
<td>K. Blennow (Sweden)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The diffusion, standardization and harmonization of cerebrospinal fluid biomarkers analysis for the diagnosis of Alzheimer’s disease</td>
<td>A. Perret-Liaudet (France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alzheimer’s Disease in the Omics Era</td>
<td>S. Bernardini (Italy)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td><strong>Educational Workshop 7 (Conference 2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Uncertainty of Measurement</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chair: M. Fick</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meeting ISO 15189 requirements for Uncertainty of Measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>M. Fick (USA)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.15-16.15</td>
<td><strong>Educational Workshop 8 (Conference 2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Medical added value of a Hb A1c separation technique for better management of diabetes patients</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chair: D.B. Sacks (USA)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comparing detection of Hb disorders by immunoassay and capillary electrophoresis during Hb A1c measurement: impact on reporting results</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>M. du Plessis (South Africa)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical added value of reported hemoglobinopathies when interpreting Hb A1c: a clinician perspective</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>N. Levitt (South Africa)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.30</td>
<td><strong>Educational Workshop 9 (Conference 1)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>First World Solutions for Resource Limited Settings</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Infectious Disease Diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>S. Miller</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Utility of Laboratory Solutions for Infectious Disease - Screening, Diagnosis &amp; Treatment monitoring</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>A. Glass</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Access to Diagnostic information and how this has played a key role in turning the tide in HIV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>TBD</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.30</td>
<td><strong>Workshop 10 (Conference 2)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Training programs for biomedical scientists/laboratory medicine specialists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chair: T. Matsha (South Africa)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Development of a training program for laboratory medical scientists and laboratory medicine specialists</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>T. Matsha (South Africa)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Development of a laboratory leadership and management programme for Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>R. Erasmus (South Africa)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>The EFLM/EC4 European Syllabus for postgraduate training in Laboratory Medicine: version 5</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>N. Jassam (UK)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Scientific Programme**

**Tuesday October 24**

<table>
<thead>
<tr>
<th>16.30-17.30</th>
<th>Workshop 11 (Conference 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interpretation &amp; commenting on clinical chemistry results</strong>&lt;br&gt;<strong>Chair</strong>: S. Vasikaran (Australia)</td>
<td></td>
</tr>
<tr>
<td>Case presentation and discussion&lt;br&gt;<strong>E. Kilpatrick (Qatar)</strong></td>
<td></td>
</tr>
<tr>
<td>Case presentation and discussion&lt;br&gt;<strong>M. J. Turzyniecka (South Africa)</strong></td>
<td></td>
</tr>
<tr>
<td>Case presentation and discussion&lt;br&gt;<strong>K. Sikaris (Australia)</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>16.30-17.30</th>
<th>Workshop 12 (Conference 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The porphyrias: from clinical presentation to a diagnosis.</strong>&lt;br&gt;<strong>The role of the laboratory profession</strong>&lt;br&gt;<strong>Chair</strong>: S. Sandberg (Norway)</td>
<td></td>
</tr>
<tr>
<td>An overview of the biochemistry of porphyrias&lt;br&gt;<strong>P. Meissner (South Africa)</strong></td>
<td></td>
</tr>
<tr>
<td>An overview of the clinical presentations of porphyrias&lt;br&gt;<strong>R. Hift (South Africa)</strong></td>
<td></td>
</tr>
<tr>
<td>How to diagnose the different porphyrias: Perspectives of the laboratory&lt;br&gt;<strong>S. Sandberg (Norway)</strong></td>
<td></td>
</tr>
</tbody>
</table>
**09.00-10.30**  SYMPOSIUM 12 (Conference 2)

**Big data and metabolomics in pediatric laboratory medicine**  
*Chair: M.J. Bennett (USA)*

- Untargeted metabolic analysis in pediatric laboratory medicine: over 30 years of experience and still learning  
  *M.J. Bennett (USA)*

- Retrospective and Prospective Data Mining to develop Robust Value Databases for Biomarkers of Pediatric Disease  
  *K. Adeli (Canada)*

- Retrospective and prospective data mining to develop continuous, covariate-adjusted reference and disease percentiles for biomarkers of metabolic disease  
  *P. Rinaldo (USA)*

**09.00-10.30**  SYMPOSIUM 13 (Conference 3)

**ISOBM/EGTM Circulating tumor markers: an update**  
*Chair: R. Molina (Spain), M.J. Duffy (Ireland)*

- Overview of Tumor Markers  
  *R. Molina (Spain)*

- PSA in Screening for Prostate Cancer: More Good Than Harm or More Harm Than Good?  
  *M.J. Duffy (Ireland)*

- How to Achieve Quality in the Measurement of Tumor Markers  
  *C. Sturgeon (UK)*
**Scientific Programme**

**Wednesday October 25**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00-10.30</td>
<td><strong>IFFC S1: IFCC SD (Conference 4)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Standardisation in laboratory medicine beyond clinical chemistry</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair:</em> P. Gillery (France)</td>
</tr>
<tr>
<td></td>
<td>Standardization: a universal need</td>
</tr>
<tr>
<td></td>
<td>P. Gillery (France)</td>
</tr>
<tr>
<td></td>
<td>Standardization of Hb A2</td>
</tr>
<tr>
<td></td>
<td>A. Mosca (Italy)</td>
</tr>
<tr>
<td></td>
<td>Standardization of autoimmune tests</td>
</tr>
<tr>
<td></td>
<td>J. Sheldon (UK)</td>
</tr>
<tr>
<td></td>
<td>Standardization in molecular diagnostics</td>
</tr>
<tr>
<td></td>
<td>D. Payne (USA)</td>
</tr>
<tr>
<td>10.00-13:30</td>
<td><strong>EXHIBITION OPEN AREA</strong></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>BREAK</strong></td>
</tr>
<tr>
<td>11.00-12.00</td>
<td><strong>Workshop 13 (Conference 1)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Bridging the gaps between laboratory medicine &amp; clinical decision making; challenges and conundrums: an interactive workshop</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair:</em> T.S. Pillay (South Africa)</td>
</tr>
<tr>
<td></td>
<td>Standardisation in the clinical laboratory: a case based perspective of why we should aim for standardisation</td>
</tr>
<tr>
<td></td>
<td>A. Don-Wauchope (Canada)</td>
</tr>
<tr>
<td></td>
<td>Clinical cut-points and reference intervals in the clinical laboratory: a case based perspective of issues in clinical practice</td>
</tr>
<tr>
<td></td>
<td>P.J. Twomey (Ireland)</td>
</tr>
<tr>
<td></td>
<td>Investigation of interferences in general chemistry and endocrine testing</td>
</tr>
<tr>
<td></td>
<td>T.S. Pillay (South Africa)</td>
</tr>
<tr>
<td>10.45-12.15</td>
<td><strong>SYMPOSIUM 14 (Conference 2)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>IFCC, TFYS Educational Workshop: ISO accreditation &amp; Quality Assurance</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> G. Beastall (UK), P. Dabla (India)</td>
</tr>
<tr>
<td></td>
<td>Understanding External Quality Assessment &amp; Internal Quality Control</td>
</tr>
<tr>
<td></td>
<td>P. Dabla (India)</td>
</tr>
<tr>
<td></td>
<td>Quality Management System for Laboratory - the French and European experience</td>
</tr>
<tr>
<td></td>
<td>G. Boursier (France)</td>
</tr>
<tr>
<td></td>
<td>Stepwise approach to laboratory accreditation in “Africa”</td>
</tr>
<tr>
<td></td>
<td>S. Olaifa (Nigeria)</td>
</tr>
<tr>
<td></td>
<td>Status of Lab Accreditation in South-Africa</td>
</tr>
<tr>
<td></td>
<td>R.T. Erasmus (South Africa)</td>
</tr>
</tbody>
</table>
**IFCC Worldlab Durban 2017**

**Scientific Programme**
**Wednesday October 25**

### 10.45-12.15 SYMPOSIUM 15 (Conference 3)

**IFCC, C-CLM - Improvement in clinical laboratory services: approaches to adding value**
**Chair:** S. Yenice (Turkey)

- From provider of results to the contributor of value: adding value to clinical laboratory services through the use of six sigma metrics
  **E. Randell (Canada)**

- Direct-to-Consumer Testing: Challenges with Lifestyle Tests
  **M. Orth (Germany)**

- Implementing value-based laboratory testing
  **A.A. Khine-Wamono (South Africa)**

### 11.00-12.00 Workshop 14 (Conference 4)

**Arab Federation Workshop: The evolution of lab medicine in the arabic countries**
**Chair:** L. Chabraoui (Morocco), B. Gouget (France)

- The role of International aids to fight AIDS, tuberculosis and malaria in developing countries with special emphasis on Africa
  **G. Shannan (Syria)**

- Conflict affected regions of the Middle East: the TB burden
  **M. Haddad (Lebanon)**

- The primary care and round table session on Quality management and EQC in the Arab Federation countries the lab: an AFBC concern
  **M.H. Kamil**

### 12.20-13.00 PLENARY 3 (Conference 1)

**Understanding the molecular genetics of Mycobacterium tuberculosis - pathways to diagnosis and therapy**
**Chair:**
**W. Bishai (USA)**

Dr. William Bishai received his MD and PhD degrees from Harvard Medical School in 1989. He did his internship and residency at the Brigham and Women’s Hospital in Boston, Massachusetts, and received fellowship training in the Division of Infectious Diseases at the Johns Hopkins School of Medicine. He was a Howard Hughes Postdoctoral Research Fellow in the laboratory of Nobel laureate, Dr. Hamilton Smith. He joined the Johns Hopkins faculty in 1994 and is currently a Professor of Medicine in the Dept. of Medicine, Division of Infectious Diseases and serves as Co-Director for the JHU Center for Tuberculosis Research. From 2010-2013 Dr. Bishai served as the founding Director of the Howard Hughes Medical Institute (HHMI)-funded KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) in Durban, South Africa, where he supervised the construction of a $40 research building and recruited seven world-class scientists to its faculty.

Dr. Bishai’s interests involve tuberculosis pathogenesis, and animal models of pulmonary infections, and bacterial respiratory tract infections. His work in South Africa led to new projects on the genomics of the M/XDR-TB strains, small molecule biomarkers in human tissue and T cell immunology of TB in the peripheral blood and lung compartments of humans. He has authored over 250 papers in peer-reviewed journals including Nature, Science, New England Journal of Medicine (Scopus H-index 58) and receives grant support from the National Institutes of Health. He has given extensive service on international conference planning committees, study sections, editorial boards, and review panels including 3 years on the WHO Stop TB Partnership Coordinating Board.

### 13.00-13.30 CLOSING CEREMONY (Conference 1)

**Congress Presidents’ Remarks**
**R. Erasmus (South Africa), T. Pillay (South Africa)**

**Welcome to Seoul 2020**
**W.K. Min (Korea), J. Song (Korea)**

**IFCC Remarks**
**M. Ferrari (Italy)**

**Korean Farewell Cocktail**
IFCC WorldLab
SEOUl 2020

24th International Congress of Clinical Chemistry and Laboratory Medicine

May 24-28, 2020
Coex, Seoul, Korea
A HEALTHIER HOSPITAL BEGINS WITH A HEALTHIER LAB

Building a healthier Africa.

Abbott is dedicated to partnering with you to elevate the health of your healthcare institution. With our personalized solutions consisting of resourceful advocates, harmonized systems, and intelligent insights, we are focused on helping you achieve measurably better healthcare performance and contribute to a healthier population.

STAY IN TOUCH WITH US!
Subscribe for WIRED e-news to keep up with the latest developments on Alinity and AlinIQ!
You have a specific question? Please send an email to wired@abbott.com or visit us online: corelab.abbott
<table>
<thead>
<tr>
<th>DATE</th>
<th>START TIME</th>
<th>END TIME</th>
<th>FUNCTION</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>20/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>IFCC EB</td>
<td>Lotheni</td>
</tr>
<tr>
<td>20/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>SD EC</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>21/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>IFCC EB</td>
<td>Lotheni</td>
</tr>
<tr>
<td>21/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>SD EC</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>21/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>EMD EC</td>
<td>Umgeni</td>
</tr>
<tr>
<td>22/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>IFCC COUNCIL</td>
<td>Mkhomazi 1 &amp; 2</td>
</tr>
<tr>
<td>22/ottobre/2017</td>
<td>13:00</td>
<td>17:00</td>
<td>C EBLM</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>22/ottobre/2017</td>
<td>13:30</td>
<td>17:00</td>
<td>C EBLM</td>
<td>Umgeni</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>08:30</td>
<td>11:30</td>
<td>C-AQ</td>
<td>Umgeni</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>09:00</td>
<td>13:00</td>
<td>C-CC</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>09:00</td>
<td>13:00</td>
<td>EMD EC</td>
<td>Injasuthi</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>AFCC</td>
<td>Lotheni</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>13:30</td>
<td>17:00</td>
<td>CPD EC</td>
<td>Injasuthi</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>14:00</td>
<td>16:00</td>
<td>WG - ICQA</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>23/ottobre/2017</td>
<td>14:00</td>
<td>17:00</td>
<td>DQCML</td>
<td>Umgeni</td>
</tr>
<tr>
<td>24/ottobre/2017</td>
<td>09:00</td>
<td>17:00</td>
<td>C - MD</td>
<td>Mzimkhulu</td>
</tr>
<tr>
<td>24/ottobre/2017</td>
<td>09:00</td>
<td>12:00</td>
<td>WG - SIA</td>
<td>Lotheni</td>
</tr>
<tr>
<td>24/ottobre/2017</td>
<td>12:30</td>
<td>14:00</td>
<td>C - CLM</td>
<td>Lotheni</td>
</tr>
<tr>
<td>24/ottobre/2017</td>
<td>14:30</td>
<td>17:30</td>
<td>ZACB</td>
<td>Lotheni</td>
</tr>
</tbody>
</table>
EXHIBITION AND SPONSORS

The exhibits of diagnostics companies in the field make up a very important part of the congress. All major international clinical-biochemistry and laboratory-medicine companies are represented. The exhibition is held in the Durban International Convention Centre.

Participants are encouraged to visit the large exhibition area, which will be open as follows:

- Monday, 23 October 10.00-17.00
- Tuesday, 24 October 10.00-17.00
- Wednesday, 25 October 10.00-13.30

Access to the exhibition area is free of charge for participants registered for the congress. However, for security reasons, anyone wishing to visit the exhibition without registering for the congress, must show at the entrance the Visitor Badge. Visitors can get the visitor badge reporting to the Visitor Registration Desk at the main entrance. The Visitor Badge does not provide admission to the lecture halls.
For more than 100 years Roche has played a pioneering role in healthcare delivery. Roche Diagnostics has the industry’s broadest range of in vitro diagnostics solutions, and serves customers spanning the entire healthcare spectrum - from research institutions, hospitals, blood banks and commercial laboratories to physicians and patients. In 2015, Roche invested CHF 9.3 billion in R&D. We believe that through continued investment in the latest innovations and our focus on creating partnerships with healthcare providers, particularly in countries with high disease burden and limited resources, Roche can make a positive, sustainable and cost-effective contribution to developing world healthcare.

The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Through our commitment to scientific rigour, we develop novel technologies, precise and robust diagnostic tests, automated systems and integrated solutions in the fields of Clinical Chemistry, Haematology, Coagulation & Immunodiagnostics, Point of Care Testing, Tissue Diagnostics and Molecular Diagnostics. Our key objective is to focus on developing medicines and diagnostics that will help patients lead better lives. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and employs more than 91,700 people worldwide. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

Roche Diagnostics is represented in South Africa and Anglophone African Markets through the Roche Diagnostics Management Centre, South Africa. We are committed to capacity building initiatives at our state-of-the-art training facility, the Roche Scientific Campus ensuring the highest quality standards of laboratory testing and enabling the upskilling of laboratory technologists, technicians and lab managers.

As part of with our quality management system, Roche Diagnostics is ISO 13485 (2016) certified. We strive to improve healthcare and peoples’ lives through the development, manufacture, supply, service and promotion of safe, effective, high-quality products and services in accordance with applicable regulations.

www.roche.com
ABBOTT DIAGNOSTICS
BOOTH 46

At Abbott, we’re committed to helping you live your best possible life through the power of health. This year, Abbott continues to unveil the Alinity™ family of next-generation diagnostics systems across clinical chemistry, immunoassay, point of care, hematology, blood and plasma screening and molecular diagnostics. Designed with universal interfaces plus common software and hardware, Abbott’s Alinity systems work together, providing greater capacity and simplifying the user experience.

The Alinity family includes AlinIQ – a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics. Both Alinity and AlinIQ will help labs and hospital systems solve some of their most pressing challenges to deliver better patient care with existing resources. More information is available at www.corelab.abbott.

The Alinity suite of instruments is currently in development. Alinity launches began in 2016 and will continue into 2018.

Abbott
100 Abbott Park Road
Abbott Park, IL, USA 60064-3500
T: 1.847.937.6100
www.abbott.com
Facebook www.facebook.com/Abbott
Twitter @AbbottNews @AbbottGlobal
Randox is shaping the future of clinical diagnostics with increased development of innovative technologies. Our passion for innovation, creativity and investment in R&D enables us to continually develop our products and evolve for the future.

Randox range of biochemistry reagents has developed significantly, from a small selection in 1982, to a test menu now comprising of over 116 biomarkers.

We also provide a range of true third party quality controls complemented by our Acusera 24.7 interlaboratory data management system and RIQAS EQA Scheme, guaranteed to simplify QC practice and ensure accurate patient diagnosis.

Add the RX series range of clinical chemistry analysers to the mix and we continue to set the benchmark for future testing. Providing semi-automated and automated solutions, the RX series is developed with the customer at the forefront.

Our position as pioneers in the health industry prevails with our revolutionary biochip array technology and the Evidence Series range of biochip analysers - advancing scientific discovery and personalised health.

Randox Laboratories Ltd.
55 Diamond Road
Crumlin - Co. Antrim
United Kingdom - BT29 4QY
T: +44 (0) 28.9442.2413
F: +44 (0) 28.9445.2912
marketing@randox.com
www.randox.com
Beckman Coulter, an operating company of Danaher Corporation develops quality clinical diagnostic instruments and assays that enhance laboratories or care networks around the world. Customers gain access to a suite of innovations in products, services and business processes that enhance clinical effectiveness and operational productivity.

The healthcare industry is changing, new challenges require new thinking, delivering fast, quality results to improve patient care. The vision of Beckman Coulter – Advancing Healthcare for Every Person, align ourselves with our customer needs.

Beckman Coulter serves customers in two segments: Diagnostics and Life Sciences. Our complete range of clinical diagnostic systems advance your lab forward for maximum productivity and reliability.

We are at the heart of discovery, assisting the world’s life sciences customers with solutions that simplify complex processes, automate procedures, and integrate work flows to accelerate breakthroughs in scientific research, medicine, and industry.

Our breadth of product solutions is as diverse as our customer segments that make up Life Sciences throughout the world today. From particle characterization for industrial use to flow cytometry for patient diagnostics, we design products of the highest quality in our quest to deliver innovative and trusted scientific solutions across the globe.
Founded in 1991, Mindray is one of the leading global providers of medical devices and solutions, committed to providing better healthcare for all. We offer a broad range of products across three primary business segments: Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging System, which have been sold to 190+ countries and regions. Mindray possesses a sound global R&D, marketing and service network with 42 international branches in 32 countries, as well as 31 branches in China. To date, we have approximately 7,300 employees from 40+ countries.

Mindray’s In-Vitro Diagnostics business has expanded to cover the areas of hematology, biochemistry, chemiluminescence immunoassay, coagulation, urinalysis, HPLC analysis, microbiology and flow cytometry, with a total of over 100 analyzer models. Together with original manufacturer reagents including 120 chemistry and immunoassay reagents, Mindray offers comprehensive laboratory solutions for medical institutions of all types and all levels. Mindray’s solutions are tailored not only towards small to mid-sized labs, we are also leading the way in automation, from our cellular analysis line to serum line connecting chemistry and immunoassay. Our IVD products are well accredited by customers worldwide, serving healthcare facilities in 150+ countries and regions.

In-Vitro Diagnostic Products

- Hematology (3 part & 5 part hematology analyzer, workstation )
- Clinical Chemistry (100~4400 tests/hour chemistry analyzer, modular system)
  - Chemiluminescence Immunoassay
  - Flow Cytometry
  - HPLC Analysis
- Urinalysis (Urine analyzer, urine sediment analyzer)
- Microbiology (microorganism analysis system, blood culture system)
- Coagulation (Semi auto, automatic coagulation analyzer)

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Mindray Building, Keji 12th Road South, High-tech Industrial Park,
Nanshan, Shenzhen 518057, P.R. China
Tel: +86 755 81888998
E-mail: intl-ivd@mindray.com
www.mindray.com
SEKISUI DIAGNOSTICS
BOOTH 14

Headquartered in Lexington, MA, for over 30 years Sekisui Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We have a history of innovation which includes, as examples, the first homogeneous test for LDL and the first plastic vacuum blood collection tube. We continue to invest in new products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan.

Sekisui Diagnostic’s workforce includes over 500 employees, in eight sites located in four countries. We are a sister company to Sekisui Medical in Japan and in China, making us a worldwide company with R&D and Manufacturing facilities on three continents.

We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through our commercial networks and partners.

Our product lines include:
Clinical chemistry systems and reagents
Coagulation systems and reagents
Point of care testing
Enzymes and specialty biochemicals

Sekisui Diagnostics, LLC
4 Hartwell Place
Lexington, MA 02421 USA
T: +1 781.652.7800
info@sekisui-dx.com
www.sekisuidiagnostics.com
Company name: Snibe (Shenzhen New Industries Biomedical Engineering Co., Ltd.)
Contact Person: Domy Chen
Address: 21st floor, Block A, Building 1, Shenzhen Software Industry Base No. 1008, Keyuan Road, Nanshan District, Shenzhen, China
Phone: 0086 755-86540750-8642
Email: sales@snibe.com
Website: www.snibe.com
Company Introduction: (150 words)
Start New Innovation, Be Excellent.

Shenzhen New Industries Biomedical Engineering Co., Ltd (Snibe) is located in the Hi-Tech Industrial Park of the Nanshan District in Shenzhen, China.

As a leading company in IVD field, Snibe has been focusing on the R&D of immunology solution since 1995. Snibe dedicated to develop, manufacture and provide extensive range of automated immunoassay solution to hospitals, medical centers, clinical laboratories etc.

MAGLUMI series, successfully launch automated chemiluminescence immunoassay (CLIA) system, is capable of providing complete solution including comprehensive test menu and variety of analyzers for laboratories' immunoassay demands. Besides, Biolumi 8000, powerful and flexible integrated system including sample processing, ISE, biochemistry and immunoassay modules, was successfully launched in 2015 for high level laboratories' demand.
Sysmex Corporation is a world leader in clinical laboratory systemisation and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for over 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on developing high-value-added testing and diagnostic technologies that are innovative, original and optimise individual health. Sysmex also leverages its state-of-the-art technologies for gene and protein analysis. Headquartered in Kobe, Japan, Sysmex has subsidiaries in North & Latin America, Europe, West & Central Africa, South Africa, China and Asia Pacific and employs over 6,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information please visit www.sysmex.co.jp/en/. For more information about Sysmex Global, please visit www.sysmex.com.

Sysmex Europe GmbH
Bornbarch 1, 22848 Norderstedt, Germany
T: +49 (40) 527.260
F: +49 (40) 527.26.100
info@sysmex-europe.com
www.sysmex-europe.com
Shaping the future of clinical diagnostics

RX series
Excellence in clinical chemistry testing

Reagents
Third party biochemistry reagents

Quality Control
Complete QC solutions for results you can trust

Evidence Series
Powered by Biochip Array Technology

JOIN OUR EDUCATIONAL WORKSHOP
Meeting ISO 15189 requirements for Uncertainty of Measurement
EduW 7 Tuesday 24th October 2017 • 14:00 – 15:00
Speaker: Margaret Fick

www.randox.com
marketing@randox.com
ABAXIS EUROPE
BOOTH 8

At Abaxis our mission is to supply point of care blood analyzers to the medical market and the veterinarian market. Abaxis provides leading edge technology, tools and services that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. Abaxis is headquartered in northern California, USA, and conducts operations around the world.

The Piccolo Xpress® is an extremely easy-to-use and reliable blood analyzer – but inside that small instrument lies sophisticated technology.

The Piccolo Xpress® is a fully automated system that delivers complete chemistry panel results in 3 easy steps and 12 minutes.

Facilities around the world have come to rely on ABAXIS for point of care diagnostics services that they need, along with the kind of customer service they deserve.

ABAXIS Europe GmbH
Bunsenstrasse 9-11
64347 Griesheim • Germany

Phone +49 6155 780 21-0
Fax +49 6155 780 21-111
E-Mail abaxis@abaxis.de

BD - BECTON DICKINSON
BOOTH 41

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes.

BD’s 40,000 associates in 50 countries work with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

www.bd.com
BINDING SITE
BOOTH 59

Binding Site is committed to improving patient lives worldwide through education, collaboration, and innovation. Visit us on stand 59 and with over 50 special protein assays available see how we can help you to maximise your protein service.

Discover our latest dedicated special protein systems. Optilite® is the latest innovation in special protein analysis, delivering, fast, high-quality, and reliable results at an impressive throughput. Now available in South Africa.

Learn how Myeloma patients benefit from Freelite® and Hevylite®. Freelite is the ONLY serum free light chain test recommended by International and national guidelines with more than 15 years of clinical evidence. The complementary ‘Hevylite‘ test adds additional information for "difficult-to-monitor" myeloma patients.

BIO-RAD LABORATORIES
BOOTH 13

Bio-Rad’s Clinical Diagnostics Group develops, manufactures, sells, and supports a large portfolio of products for medical screening and diagnostics. Bio-Rad is the number one specialty diagnostic company in the world.

The company is well known for its diabetes monitoring products, its quality control (QC) systems, blood virus testing and detection, blood typing, toxicology, genetic disorders testing, specialty chemistry, molecular pathology, and internet-based software products.
DIASOURCE IMMUNOASSAYS

BOOTH 20

30 years of experience in IVD (kits and instrumentation)

DIAsource ImmunoAssays®, an international diagnostic company based in Belgium, develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.

We are committed to Vitamin D, including IVD and RUO Products. Our panel of assays allows the performant detection and measurement of various forms of Vitamin D metabolites: 25OH Vitamin D, 1,25(OH)2 Vitamin D.

Constantly looking for new technologies and applications, we put our expertise in the development of new antibodies and assays to measure relevant biomarkers. We are strengthening our position in the diagnostic market by validating our ELISA assays on our open automate. These innovation mark a turning point for our company, and makes of DIAsource, already renowned in the RIA market, a complete diagnostic provider.

We also provide selected instrumentation: we offer Elisa reader, washer and shaker, along with open and closed fully automated Elisa platforms helping our customers to automate their tests. Present in more than 75 countries through his professional network of 80 distributors, DIAsource ImmunoAssays® also sells directly his own products and products from other selected manufacturers to IVD laboratories in some European countries.

In January of 2016 DIAsource ImmunoAssays® has been acquired by Anteo (www.anteodx.com).

www.diasource-diagnostics.com

EUROIMMUN

BOOTH 71

EUROIMMUN is an international provider of medical laboratory products for autoimmune diagnostics, infection diagnostics, allergology and molecular diagnostics. The company’s portfolio encompasses indirect immunofluorescence, ELISA, immunoblot, radioimmunoassay and microarray test systems and spans over a thousand diagnostic parameters. State-of-the-art instruments and software provide efficient automation of analyses, increasing productivity and reliability in routine diagnostics. EUROIMMUN scientists participate in many international research projects, contributing to cutting-edge advances in laboratory diagnostics. Pioneering developments include BIOCHIP technology, designer antigens, recombinant-cell IFT and multiplex molecular allergology systems. A renowned reference laboratory and a quality assurance programme are part of EUROIMMUN’s expert technical service.

EUROIMMUN AG
Main Office
Seekamp 31
23560 Luebeck
Germany
Tel.: +49 451 58 55-0
Fax: +49 451 58 55-591
E-Mail: info@euroimmun.de

EUROIMMUN South Africa Pty Ltd.
Mrs Claudia Ohst
39 Clifton Crescent, Parklands 7441
Cape Town
South Africa
Tel.: +27 215577666
Fax.: +27 215577666
E-Mail: c.ohst@euroimmun.co.za

www.euroimmun.de
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Our products range from specialized manual testing to fully automated routine testing and they cover areas such as infectious diseases, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Over the last 25 years we have acquired solid experience in bringing robust automated immunoassay testing solutions to the market, such as the Lumipulse® series available in Europe, US and Asia. We are widely recognized as the world-wide market leader in oncology for routine and novel markers. Under the name Inno genetics, we have been pioneering in the field of molecular diagnostics and multiparameter testing.

Founded in 1950, Fujirebio is a member of Miraca Group (listed on the Tokyo Stock Exchange – TYO: 4544).

Fujirebio Europe N.V.
Technologiekpark 6
B-9052 Gent
Belgium
Tel: +32 9 329 1329
www.fujirebio-europe.com
contact person: Rikkert Maertens
 e-mail: rikkert.maertens@fujirebio.com

GeneReach Biotechnology Corporation, headquartered in Taiwan, is dedicated to bringing the innovation to global health management. By developing, manufacturing and marketing products for applied nucleic acid detection technology, we offer pathogen detection platforms, including equipment and reagents, to multiple industries. The applications of our products include human health industries, aquaculture, agriculture, food, companion animal and livestock. Our products are manufactured in compliance with the requirements of Good Manufacturing Practices (GMP) in addition to ISO 9001 and ISO 13485. Developing the high performance and user friendly products is the major driving force of our research and development team. Based on this philosophy, GeneReach Biotechnology Corporation manufactures products which are reliable, affordable and easy to perform. Our goal is to provide the best detection products and service worldwide and down to the extreme of Point of Need market.

Mission & Vision
Our mission is to be a premier provider of molecular diagnostic products that are capable, affordable, portable, and adaptable for point-of-need application. Our vision is “enrich your life through technology innovation”. Our platform technologies will revolutionize health management industry, help more lives and guarantee satisfied customers.

GeneRadar Biotechnology Corp.(Xiamen)
Unit 701, Technology Service Center, No.120, Xinyuan Road, Haicang District, Xiamen, Fujian
TEL:+86-(0)592-6895171
FAX:+86-(0)592-6895170
ILEX SOUTH AFRICA was established in 1992 as a wholly owned subsidiary of ILEX Medical LTD. Today ILEX South Africa is one of the major suppliers of IVD products in South Africa. Our products included Critical Care, Molecular Diagnostics, Immunology, Protein electrophoresis, as well as our proprietary Laboratory Information System (LIS), eLab.

The cornerstone of our company’s success has been a marketing strategy that focuses on customer needs and project-based implementation. This ensures that we provide services and products of high quality. Ilex South Africa strives for service excellence and market leadership in niche diagnostic segments.

Our team of professional staff enable us to provide an exceptional service countrywide to suit specific customer needs whilst adhering the Ilex company values of Pride, Integrity, Commitment and Service Excellence.

ILEX
BOOTH 63

Sebia a global specialty diagnostic company, develops, manufactures and commercializes IVD tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobin disorders.

Sebia’s focus on electrophoresis techniques enables it to maintain a sustained R&D program, providing access to genuine innovations in any lab. Both agarose gel and capillary assays, and their dedicated automation, are designed to be integrated into the same routine workflow; for gel (Assist, Hydrasys 2 Scan) and for capillary electrophoresis (Capillaries 3 TERA, stand alone or in work cell configuration up to three instruments with tube loader, Capillaries 2 Flex Piercing, Minicap Flex Piercing).

More recently Sebia completed its Myeloma product line, with two important additions, Hydrashift daratumumab, reagent to be used with the Hydragel IF test to mitigate the DARZALEX® interference, and two new generations sFLC assays, Seralite serum and Sebia FLC kappa and lambda kits.

SEBIA
BOOTH 63

Ilex South Africa (Pty) Ltd.
19 Polo Crescent
Van Reenen Avenue
Woodmead Office Park
2191 Woodmead
Tel: +27 11 804-4004
Fax: +27 11 804-1120
e-mail: mail@ilex.co.za
www.ilex.co.za

Sebia
Parc Technologique Léonard de Vinci
27 rue Léonard de Vinci
CP 8010 Lisses – 91008 EVRY Cedex
Tel: 01 69 89 80 80
www.sebia.com
IMMUNDIAGNOSTIK AG
BOOTH 9

Immundiagnostik AG is a globally operating diagnostics company represented in over 30 countries. We focus on the development and production of innovative immunoassays (ELISA, EIA) and other analytical detection methods (e.g. HPLC, LC-MS/MS and PCR) for medical routine and research.

Our mission is to provide effective tools for prevention, differential diagnosis and therapy monitoring in the areas of gastroenterology, cardiovascular diseases, disorders of the skeletal system and oxidative stress.

The product portfolio is completed by a broad range of antibodies and antigens. Our business relations include contract analyses for diagnostic laboratories and academic research institutions, esp. in context with clinical trials.

Securing progress: Our comprehensive range of products is continuously refuelled by a rich pipeline of proprietary developments. With a headcount of more than 80 employees, Immundiagnostik’s headquarter is located in Bensheim, south-western Germany.

Immundiagnostik AG
Stubenwald-Allee 8a
DE-64625 Bensheim
Dr. Karl Florian Wintgens
Mobile: 0049 172 718 9895
k.f.wintgens@immundiagnostik.com

ORTHO CLINICAL DIAGNOSTICS

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks, and labs in more than 120 countries, Ortho’s high-quality products and services enable healthcare professionals to make better-informed treatment decisions.

For the immunohematology community, Ortho’s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit.

Ortho brings sophisticated testing technologies, automation, information management, and interpretation tools to clinical laboratories around the world to help them run more efficiently, effectively and improve patient care.

Ortho’s purpose is to improve and save lives with diagnostics and it does that by reimagining what’s possible. This is what has defined Ortho for more than 75 years, and it’s what drives Ortho forward.

Ortho Clinical Diagnostics
1001 US Highway 202
Raritan, NJ 08869
USA
www.orthoclinicaldiagnostics.com
THE SCIENTIFIC GROUP
BOOTH 43

The Scientific Group is a Clinical Diagnostic and Life Science company with 32 years' experience in sales and service in the science and healthcare industry.

Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits. Our success is based on consistently achieving standards of excellence in the quality of all we do.

Test kits manufactured are used in the clinical laboratory and point-of-care segments of the diagnostic market, to detect infectious diseases, sexually transmitted diseases, autoimmune disorders, cardiac arrest, haemoglobin disorders, and in the detection, monitoring and control of diabetes. We also provide significant levels of raw material to the life sciences industry.

Quoted on the NASDAQ exchange, and with facilities spanning Europe and America, our products are sold in more than 110 countries. We reach our customers worldwide by combining the skills of our own sales force with a network of international distributors and strategic partners.

Trinity Biotech
YOUR DIAGNOSTICS PARTNER

Come see us in Hall 3 at Booth 43 for more information or for a full demonstration on one of our best-in-class analysers for HbA1c, haemoglobinopathies and autoimmunity

In cooperation with our trusted Distribution Partner in South Africa:
SPONSORS

ABAXIS EUROPE
ABBOTT
BD
BECKMAN
BINDING SITE
BIO-RAD
DIASOURCE
ELITECH GROUP
EUROIMMUN
FUJIREBIO
GENERACH BIOTECHNOLOGY
ILEX
IMMUNDIAGNOSTIK
MINDRAY
ORTHO CLINICAL DIAGNOSTICS
RANDOX
ROCHE
SEBIA
SEKISUI
SNIBE
SYSMEX
THE SCIENTIFIC GROUP
Stay ahead with Sysmex

Come and visit us in Hall 3, booth 30 – 33

UN-Series
The modular way of urinalysis

UC-1000
Semi-automated urine chemistry analyser

XN-1500
Count. Smear. Stain. All-in-one haematology.

CyFlow® Ploidy
Analyser
High-resolution DNA analysis

Educational Workshop
Monday
14:00 – 15:00
Room 2

www.sysmex-europe.com
### SATellite MeeTinGS

**XIV International Congress of Paediatric Laboratory Medicine**  
20-22 October 2017  
Durban  
Blue Waters Hotel  
www.icplm2017.org

**POCT Satellite Meeting**  
22 October 2017  
Durban  
ICC Center

**Intelligent Clinical Laboratory Management: Impacts on Quality System Improvement**  
21 October 2017  
Hotel Hilton Durban  
Durban

**Satellite Meeting - Biomarkers for Diabetes**  
26-27 October 2017  
Cape Town

### How To Get To Durban

**By Plane**

Access to South Africa is easy!

Fast Facts: 76 Countries are exempt for South African Visas | 32 International Airlines fly into South Africa direct | Direct flights into South Africa depart from more than 60 airports internationally, including Frankfurt, Munich, Heathrow, New York, Buenos Aires and Beijing | 6 Domestic Airlines currently fly between the major city centres including Airlink, British Airways t/a Comair, Kulula.com, Mango Airlines, South African Airways and South African Express International Airports: [www.airports.co.za](http://www.airports.co.za)

King Shaka International Airport (DUR) – The airport is 22 miles (32km) north of Durban:  
O.R. Tambo International Airport (ORTIA)(JNB) – The airport is 14 miles (22km) east of Johannesburg: Cape Town International Airport (CPT) – The airport is 13 miles (20km) east of Cape Town.

**By Car**

From Johannesburg, OR Tambo International Airport: 577kms approx.  
6½ hours of which 555kms are the N3 highway.  
From Cape Town, International Airport:  
1640 kms approx. 20 hours of which 1500kms of which are the N2 highway.
**GENERAL INFORMATION**

**DELEGATES REGISTRATION**

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Registration</td>
<td>€ 750</td>
</tr>
<tr>
<td>Young Registration (≤35 years)</td>
<td>€ 375</td>
</tr>
<tr>
<td>Day Registration</td>
<td>€ 250</td>
</tr>
</tbody>
</table>

The full registration and young registration fees include:
- entrance to plenary lectures, symposia, industry-sponsored workshops, posters sessions and exhibition
- certificate of attendance

The day registration fee includes, for the day of registration only:
- entrance to plenary lectures, symposia, industry-sponsored workshops, posters sessions and exhibition
- abstracts book
- certificate of attendance

**LUNCH SYMPOSIA**

Lunch Symposium attendance includes a packed lunch on 23rd and 24th October. The lunch box can be picked up from 12.30 to 14.30 at Baobab Café/ICC Coffee Shop on Level 3.

**BREAKFAST SYMPOSIUM**

Breakfast Symposium attendance includes a coffee station available on 25th October at the entrance of the meeting room.

**REMITTANCE**

On-site registrations may be paid only by credit card or cash. Cheques will not be accepted.

**REGISTRATION DESK**

The registration desk, located at the entrance of the congress centre, is open as follows:

- Sunday, 22 October 2017: 12.00-20.00
- Monday, 23 October 2017: 08.00-17.30
- Tuesday, 24 October 2017: 08.00-17.30
- Wednesday, 25 October 2017: 07.15-14.00
GENERAL INFORMATION

CURRENCY
Registration fees and charges for all events related to the IFCC-Worldlab Durban 2017 Congress as well as hotel cost must be paid in euros.

CANCELLATION OF THE CONGRESS
The congress secretariat reserves the right to cancel the congress, shift venue, or change dates without notice, in case of “force majeure”. Neither MZ Congressi nor the Congress Organising Committee shall be liable for any damage claims.

LIABILITY AND INSURANCE
Registration fees do not include the insurance of participants against personal accidents, sickness and cancellations by any party, theft, loss or damage to personal possessions. Participants are advised to take out adequate personal insurance to cover travel, accommodation, cancellation and personal effects.

EXHIBITION AREA
The exhibits of diagnostics companies in the field make up a very important part of the congress. All major international clinical-biochemistry and laboratory-medicine companies are represented. The exhibition is held in the Durban International Convention Centre.

Participants are encouraged to visit the large exhibition area, which will be open as follows:
Monday, 23 October 10.00-17.00
Tuesday, 24 October 10.00-17.00
Wednesday, 25 October 10.00-13.30

Access to the exhibition area is free of charge for participants registered for the congress. However, for security reasons, anyone wishing to visit the exhibition without registering for the congress, must show at the entrance the Visitor Badge. Visitors can get the visitor badge reporting to the Visitor Registration Desk at the main entrance. The Visitor Badge does not provide admission to the lecture halls.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be issued to properly registered attendees, for the day(s) they actually take part in the congress. Certificates of attendance must be picked up at the registration desk just before departure.
NAME BADGE
All participants will receive a name badge when they check-in at the registration desk. The badge must be worn at all times because only registered participants will be admitted to the scientific sessions. It must also be worn at the social events organised as part of the congress.

CONGRESS KIT
The congress kit can be collected at the registration desk.

WIRELESS CONNECTION
IFCC WorldLabDurban is offering free WiFi for delegates in all Congress Centre.
Network: Durban ICC Wifi
Password: Convention1

AUDIOVISUAL CENTER
The audiovisual centre is located on Level 0 of the Congress Centre. Speakers are kindly requested to bring their presentation to the audiovisual centre on a USB drive at least two hours before the presentation is scheduled. Personal laptops cannot be connected to the system.

POSTERS
Posters are displayed in the exhibition area, Level 0, of the Congress Centre. Posters are arranged by topic and displayed on two different days:
Monday 23 October 10.00-17.00
Tuesday, 24 October 10.00-17.00

Posters are numbered and must be on display on the day that the Organising Secretariat assigned the authors, according to the following schedule only:
Set-up 09.30-10.00
Removal 17.30-18.00

Posters differ by topic every day and the Organising Secretariat declines any responsibility for posters left on display afterwards.
In order to encourage discussions about posters, the poster Presenter must bat the assigned poster panel from 13.00 to 14.00
GENERAL INFORMATION

ORGANISING SECRETARIAT
MZ Congressi
Via Carlo Farini 81 - 20159 Milan - Italy
Tel. +39 02 66802323 Fax +39 02 6686699
Email: info@durban2017.org

LANGUAGE
The official language of the Congress will be English. Simultaneous translation will not be provided.

CURRENCY
The South African Rand is the currency in South Africa (ZA, ZAF). The South African Rand is also known as Rands. The symbol for ZAR can be written R. The South African Rand is divided into 100 cents.

ELECTRICITY
220/230 V - 50 Hz, Plug Type M

USEFUL NUMBERS
+27 10111 - National Flying Squad
+27 10177 - Ambulance
+27 372011 - Rescue Services
+27 313035787 - Taxi Service

ACCOMMODATION
XL Millennium
Lower Vasco Boulevard
Goodwood
Cape Town - South Africa
TEL: 021 590 7900
Email: lindab@millenniumtravel.co.za
Reimagining What’s Possible.

Our purpose is to improve and save lives with diagnostics. It’s what has defined us for more than 75 years. It’s what drives us forward. It’s the Ortho difference.

Discover what’s possible at orthoclinicaldiagnostics.com.

Ortho Clinical Diagnostics
GENERAL INFORMATION

IFCC WORLDLAB DURBAN APP

Using the WorldApp you can display the following:
- Scientific Programme
- Posters
- General Information
- Sponsors and Exhibitors
- Push Notifications with the latest news
- Breaking News

SPONSORED BY:

CONGRESS VENUE

DURBAN INTERNATIONAL CONVENTION CENTRE

45 Bram Fischer Road
Durban, 4001
South Africa
ELITechGroup

Bench-Top Instruments

CLINICAL CHEMISTRY SYSTEMS

Scaleable Solutions

A comprehensive range of bench-top chemistry systems

Selectra ProM

Setting a new standard in benchtop chemistry systems with next generation Selectra Touch Pro software

Selectra ProXL

The most productive Selectra Pro System. Offers an ideal solution of proven quality, performance and value.

Selectra ProS

Fully featured compact system with the ease-of-use to boost productivity for today’s laboratory

Visit us at:
MEDICA, Düsseldorf (Germany)
13-16 November 2017 - Hall 3

Follow us on:

www.elitechgroup.com
info@elitechgroup.com